169 related articles for article (PubMed ID: 7539559)
21. Delayed/salvage radiation therapy in patients with elevated prostate specific antigen levels after radical prostatectomy. A long term follow-up.
Medini E; Medini I; Reddy PK; Levitt SH
Cancer; 1996 Sep; 78(6):1254-9. PubMed ID: 8826948
[TBL] [Abstract][Full Text] [Related]
22. Salvage radiotherapy for prostate cancer recurrence after cryosurgical ablation.
Burton S; Brown DM; Colonias A; Cohen J; Miller R; Rooker G; Benoit R; Merlotti L; Quinn A; Kalnicki S
Urology; 2000 Nov; 56(5):833-8. PubMed ID: 11068312
[TBL] [Abstract][Full Text] [Related]
23. Is anastomotic biopsy necessary before radiotherapy after radical prostatectomy?
Koppie TM; Grossfeld GD; Nudell DM; Weinberg VK; Carroll PR
J Urol; 2001 Jul; 166(1):111-5. PubMed ID: 11435834
[TBL] [Abstract][Full Text] [Related]
24. Does seminal vesicle-sparing robotic radical prostatectomy influence postoperative prostate-specific antigen measured with an ultrasensitive immunoassay?
Burkhardt O; Neuenschwander JE; John H; Randazzo M
Swiss Med Wkly; 2018 Nov; 148():w14685. PubMed ID: 30474852
[TBL] [Abstract][Full Text] [Related]
25. Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy.
Stephenson AJ; Shariat SF; Zelefsky MJ; Kattan MW; Butler EB; Teh BS; Klein EA; Kupelian PA; Roehrborn CG; Pistenmaa DA; Pacholke HD; Liauw SL; Katz MS; Leibel SA; Scardino PT; Slawin KM
JAMA; 2004 Mar; 291(11):1325-32. PubMed ID: 15026399
[TBL] [Abstract][Full Text] [Related]
26. Clinicopathological features of patients with biochemical recurrence after radical prostatectomy without progressive rise in serum prostate-specific antigen.
Miyake H; Hara I; Kurahashi T; Muramaki M; Yamanaka K; Inoue TA; Fujisawa M
Urol Int; 2006; 77(3):200-4. PubMed ID: 17033205
[TBL] [Abstract][Full Text] [Related]
27. Radiation therapy for the management of biopsy proved local recurrence after radical prostatectomy.
Rogers R; Grossfeld GD; Roach M; Shinohara K; Presti JC; Carroll PR
J Urol; 1998 Nov; 160(5):1748-53. PubMed ID: 9783945
[TBL] [Abstract][Full Text] [Related]
28. The source of pretreatment serum prostate-specific antigen in clinically localized prostate cancer--T, N, or M?
Zagars GK; Kavadi VS; Pollack A; von Eschenbach AC; Sands ME
Int J Radiat Oncol Biol Phys; 1995 Apr; 32(1):21-32. PubMed ID: 7536722
[TBL] [Abstract][Full Text] [Related]
29. Impact of postprostatectomy prostate-specific antigen nadir on outcomes following salvage radiotherapy.
Garg MK; Tekyi-Mensah S; Bolton S; Velasco J; Pontes E; Wood DP; Porter AT; Forman JD
Urology; 1998 Jun; 51(6):998-1002. PubMed ID: 9609639
[TBL] [Abstract][Full Text] [Related]
30. Prostate-specific antigen (PSA) in the monitoring of prostate cancer after radical prostatectomy and external beam radiation.
Schaefer U; Witt F; Schueller P; Micke O; Willich N
Anticancer Res; 2000; 20(6D):4989-92. PubMed ID: 11326654
[TBL] [Abstract][Full Text] [Related]
31. Adjuvant radiation therapy in patients with detectable prostate specific antigen following radical prostatectomy.
Link P; Freiha FS; Stamey TA
J Urol; 1991 Mar; 145(3):532-4. PubMed ID: 1705294
[TBL] [Abstract][Full Text] [Related]
32. Prognostic significance of undetectable ultrasensitive prostate-specific antigen nadir after radical prostatectomy.
Hong SK; Park HZ; Lee WK; Kim DS; Lee JS; Doo SH; Jeong SJ; Yoon CY; Byun SS; Lee SE
Urology; 2010 Sep; 76(3):723-7. PubMed ID: 20579699
[TBL] [Abstract][Full Text] [Related]
33. Radiotherapy for men with isolated increase in serum prostate specific antigen after radical prostatectomy.
Macdonald OK; Schild SE; Vora SA; Andrews PE; Ferrigni RG; Novicki DE; Swanson SK; Wong WW
J Urol; 2003 Nov; 170(5):1833-7. PubMed ID: 14532786
[TBL] [Abstract][Full Text] [Related]
34. Ultrasensitive prostate specific antigen and its role after radical prostatectomy: a systematic review.
Tilki D; Kim SI; Hu B; Dall'Era MA; Evans CP
J Urol; 2015 May; 193(5):1525-31. PubMed ID: 25444980
[TBL] [Abstract][Full Text] [Related]
35. Clinical utility of indium 111-capromab pendetide immunoscintigraphy in the detection of early, recurrent prostate carcinoma after radical prostatectomy.
Raj GV; Partin AW; Polascik TJ
Cancer; 2002 Feb; 94(4):987-96. PubMed ID: 11920467
[TBL] [Abstract][Full Text] [Related]
36. Outcomes of salvage radiotherapy for recurrent prostate cancer after radical prostatectomy.
Lee EK; Mui WH; Chan AW; Tung Y; Wong FC
Hong Kong Med J; 2018 Jun; 24(3):218-225. PubMed ID: 29807949
[TBL] [Abstract][Full Text] [Related]
37. Identification of factors predicting response to adjuvant radiation therapy in patients with positive margins after radical prostatectomy.
Kamat AM; Babaian K; Cheung MR; Naya Y; Huang SH; Kuban D; Babaian RJ
J Urol; 2003 Nov; 170(5):1860-3. PubMed ID: 14532793
[TBL] [Abstract][Full Text] [Related]
38. Three-year postoperative ultrasensitive prostate-specific antigen following open radical retropubic prostatectomy is a predictor for delayed biochemical recurrence.
Malik RD; Goldberg JD; Hochman T; Lepor H
Eur Urol; 2011 Sep; 60(3):548-53. PubMed ID: 21652145
[TBL] [Abstract][Full Text] [Related]
39. Effect of higher radiation dose on biochemical control after radical prostatectomy for PT3N0 prostate cancer.
Valicenti RK; Gomella LG; Ismail M; Mulholland SG; Petersen RO; Corn BW
Int J Radiat Oncol Biol Phys; 1998 Oct; 42(3):501-6. PubMed ID: 9806507
[TBL] [Abstract][Full Text] [Related]
40. Prostate specific antigen only progression of prostate cancer.
Moul JW
J Urol; 2000 Jun; 163(6):1632-42. PubMed ID: 10799151
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]